Drug Failure Deals AstraZeneca Fresh Blow
22568
AstraZeneca Plc suffered its third  setback in two months on Friday as lung cancer drug Iressa  failed to help patients live longer in a major clinical trial,  sending its shares down as much as 9.2 percent.
455403
The biopharma announces a dramatic shift following the failure of its lead drug.
113293
AstraZeneca was dealt a blow yesterday when an official from the US&#39;s drugs watchdog questioned whether one of its key products ought to be sold in the world&#39;s largest pharmaceuticals market.
691286
Drug maker AstraZeneca PLC said Friday that the Food and Drug Administration did not approve its orally taken blood thinner Exanta.
22799
A U.S. panel of medical experts recommended on Friday that U.S. regulators reject AstraZeneca's   application to sell its anti-clotting drug Exanta.
12314
Its Alzheimer's treatment flops in testing, on the heels of FDA disapproval of another Neurochem drug.
454431
The drug company's experimental treatment for Alzheimer's  failed to prove effective in a big clinical trial. The stock  closed Tuesday at $45.85 on the New York Stock Exchange before  falling 10 percent in after-hours trading following release of  the trial results.
564304
WASHINGTON/LONDON  - An FDA review AstraZeneca  Plc's  under the name Coumadin.
353921
Twenty-nine patients who took  AstraZeneca Plc's AZN.L AZN.N anti-cholesterol drug Crestor  have developed kidney damage, a U.S. consumer group said on  Friday as it called again for a ban on the medicine.
37345
Teva's lupus drug fails to meet its primary endpoint in its phase 2 trial.
442644
AstraZeneca Plc has withdrawn its marketing application for lung cancer pill Iressa in Europe after the drug failed to help patients live longer in a clinical study, Europe's third largest drugmaker said on Tuesday.
619726
AstraZeneca, the Anglo-Swedish pharmaceutical group, suffered another setback when it suspended marketing of Iressa, a lung cancer drug launched this year.
643643
Drug-maker posts tepid results as it bides time before new products hit the market.
509522
In an announcement that took doctors, patients and stock analysts by complete surprise, lung cancer drug Iressa failed to help patients live longer in a significant clinical trial.
677416
Rivals lead to lower sales of the pharmaceutical's only marketed drug.
443779
Investors in pharmaceuticals were dealt a triple whammy on Friday as Pfizer Inc, AstraZeneca Plc and Eli Lilly and Co all shocked the market with bad news about key products.
664897
Astrazeneca Admitted yesterday to an over-optimistic culture within its drug development division as it revealed its recently launched lung cancer pill did not improve patients&#39; life expectancy.